Ken Griffin Day One Biopharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,400 shares of DAWN stock, worth $151,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,400

Previous 9,600 91.67%

Holding current value

$151,800

Previous $133,000 75.19%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$12.46 - $16.39 $1.58 Million - $2.08 Million	127,052 Added 26.24%	611,313 $7.75 Million
Q3 2024 Nov 14, 2024	BUY	$12.72 - $16.03 $1.46 Million - $1.84 Million	114,653 Added 31.02%	484,261 $6.75 Million
Q2 2024 Aug 14, 2024	BUY	$12.03 - $17.69 $3.88 Million - $5.7 Million	322,343 Added 681.99%	369,608 $5.09 Million
Q1 2024 May 15, 2024	BUY	$13.56 - $17.46 $542,372 - $698,365	39,998 Added 550.41%	47,265 $780,000
Q4 2023 Feb 14, 2024	BUY	$9.68 - $15.37 $4,965 - $7,884	513 Added 7.6%	7,267 $106,000
Q3 2023 Nov 14, 2023	SELL	$11.22 - $14.86 $8.59 Million - $11.4 Million	-765,402 Reduced 99.13%	6,754 $82,000
Q2 2023 Aug 14, 2023	BUY	$11.74 - $14.47 $4.44 Million - $5.47 Million	378,072 Added 95.94%	772,156 $9.22 Million
Q1 2023 May 15, 2023	BUY	$12.75 - $23.41 $4.94 Million - $9.06 Million	387,213 Added 5635.47%	394,084 $5.27 Million
Q4 2022 Feb 14, 2023	SELL	$18.77 - $22.0 $771,015 - $903,694	-41,077 Reduced 85.67%	6,871 $147,000
Q3 2022 Nov 14, 2022	SELL	$16.44 - $26.57 $194,912 - $315,013	-11,856 Reduced 19.82%	47,948 $961,000

Others Institutions Holding DAWN

# of Institutions

176

Shares Held

77.8M

Call Options Held

139K

Put Options Held

253K

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $606M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account